|
WO2010084160A1
(en)
|
2009-01-21 |
2010-07-29 |
Oryzon Genomics S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
|
JP5699152B2
(ja)
|
2009-09-25 |
2015-04-08 |
オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． |
リジン特異的デメチラーゼ−１阻害剤およびその使用
|
|
EP2486002B1
(en)
|
2009-10-09 |
2019-03-27 |
Oryzon Genomics, S.A. |
Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
|
|
US9186337B2
(en)
|
2010-02-24 |
2015-11-17 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
|
|
WO2011106574A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Inhibitors for antiviral use
|
|
JP5868948B2
(ja)
|
2010-04-19 |
2016-02-24 |
オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． |
リジン特異的脱メチル化酵素１阻害薬およびその使用
|
|
US9006449B2
(en)
|
2010-07-29 |
2015-04-14 |
Oryzon Genomics, S.A. |
Cyclopropylamine derivatives useful as LSD1 inhibitors
|
|
WO2012013728A1
(en)
|
2010-07-29 |
2012-02-02 |
Oryzon Genomics S.A. |
Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
|
|
WO2012045883A1
(en)
|
2010-10-08 |
2012-04-12 |
Oryzon Genomics S.A. |
Cyclopropylamine inhibitors of oxidases
|
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
|
EP2712315B1
(en)
|
2011-02-08 |
2021-11-24 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
|
CN103842332B
(zh)
*
|
2011-08-09 |
2016-08-17 |
武田药品工业株式会社 |
环丙胺化合物
|
|
AU2012324803B9
(en)
|
2011-10-20 |
2017-08-24 |
Oryzon Genomics, S.A. |
(hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
|
|
SG11201401066PA
(en)
|
2011-10-20 |
2014-10-30 |
Oryzon Genomics Sa |
(hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
|
|
CN104981458B
(zh)
|
2012-10-02 |
2017-07-21 |
吉利德科学公司 |
组蛋白去甲基化酶抑制剂
|
|
WO2014058071A1
(ja)
|
2012-10-12 |
2014-04-17 |
武田薬品工業株式会社 |
シクロプロパンアミン化合物およびその用途
|
|
EP2740474A1
(en)
|
2012-12-05 |
2014-06-11 |
Instituto Europeo di Oncologia S.r.l. |
Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
|
|
SG10201707027SA
(en)
|
2013-02-27 |
2017-09-28 |
Epitherapeutics Aps |
Inhibitors of histone demethylases
|
|
WO2014194280A2
(en)
*
|
2013-05-30 |
2014-12-04 |
The Board of Regents of the Nevada System of Higher Education on behalf of the University of |
Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells
|
|
JP6392344B2
(ja)
*
|
2013-07-25 |
2018-09-19 |
ドン−ア エスティ カンパニー リミテッド |
ベンズアミド誘導体の製造方法、その製造に使用される新規な中間体及び該中間体の製造方法
|
|
EP3030323B1
(en)
|
2013-08-06 |
2019-04-24 |
Imago Biosciences Inc. |
Kdm1a inhibitors for the treatment of disease
|
|
EP3392244A1
(en)
|
2014-02-13 |
2018-10-24 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
|
US9493450B2
(en)
|
2014-02-13 |
2016-11-15 |
Incyte Corporation |
Cyclopropylamines as LSD1 inhibitors
|
|
PE20161573A1
(es)
|
2014-02-13 |
2017-01-19 |
Incyte Corp |
Ciclopropilamina como inhibidor de la lsd1
|
|
WO2015123437A1
(en)
*
|
2014-02-13 |
2015-08-20 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
|
CN104042616B
(zh)
*
|
2014-02-20 |
2016-08-24 |
复旦大学附属眼耳鼻喉科医院 |
赖氨酸特异性去甲基化酶1抑制剂的应用
|
|
PE20161441A1
(es)
|
2014-04-11 |
2017-01-21 |
Takeda Pharmaceuticals Co |
Compuesto de ciclopropanamina y sus usos
|
|
PE20161438A1
(es)
|
2014-05-01 |
2017-01-18 |
Celgene Quanticel Res Inc |
Inhibidores de desmetilasa 1 especifica a lisina
|
|
WO2016007727A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as lsd1 inhibitors
|
|
WO2016007722A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as lsd1 inhibitors
|
|
TWI687419B
(zh)
|
2014-07-10 |
2020-03-11 |
美商英塞特公司 |
作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
|
|
US9695180B2
(en)
|
2014-07-10 |
2017-07-04 |
Incyte Corporation |
Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
|
|
KR20170040805A
(ko)
|
2014-08-27 |
2017-04-13 |
길리애드 사이언시즈, 인코포레이티드 |
히스톤 데메틸라제를 억제하기 위한 화합물 및 방법
|
|
WO2016055935A1
(en)
*
|
2014-10-06 |
2016-04-14 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
|
|
EA039196B1
(ru)
*
|
2014-10-08 |
2021-12-16 |
Инсайт Корпорейшн |
Циклопропиламины в качестве ингибиторов lsd1
|
|
CN107438593B
(zh)
*
|
2015-01-30 |
2020-10-30 |
基因泰克公司 |
治疗化合物及其用途
|
|
ES3005884T3
(en)
|
2015-02-12 |
2025-03-17 |
Imago Biosciences Inc |
A kdm1a inhibitor and its use in therapy
|
|
PE20180455A1
(es)
|
2015-04-03 |
2018-03-05 |
Incyte Corp |
Compuestos heterociclicos como inhibidores de lsd1
|
|
US10526287B2
(en)
|
2015-04-23 |
2020-01-07 |
Constellation Pharmaceuticals, Inc. |
LSD1 inhibitors and uses thereof
|
|
EP3090998A1
(en)
|
2015-05-06 |
2016-11-09 |
F. Hoffmann-La Roche AG |
Solid forms
|
|
US20180284095A1
(en)
|
2015-06-12 |
2018-10-04 |
Oryzon Genomics, S.A. |
Biomarkers associated with lsd1 inhibitors and uses thereof
|
|
EP3307267B1
(en)
|
2016-06-10 |
2019-04-10 |
Oryzon Genomics, S.A. |
Multiple sclerosis treatment
|
|
WO2017013061A1
(en)
|
2015-07-17 |
2017-01-26 |
Oryzon Genomics, S.A. |
Biomarkers associated with lsd1 inhibitors and uses thereof
|
|
SG10202001219UA
(en)
*
|
2015-08-12 |
2020-03-30 |
Incyte Corp |
Salts of an lsd1 inhibitor
|
|
MA42683A
(fr)
|
2015-08-27 |
2018-07-04 |
Genentech Inc |
Composés thérapeutiques et leurs méthodes utilisation
|
|
WO2017079476A1
(en)
*
|
2015-11-05 |
2017-05-11 |
Mirati Therapeutics, Inc. |
Lsd1 inhibitors
|
|
JP2018535234A
(ja)
|
2015-11-25 |
2018-11-29 |
ジェネンテック， インコーポレイテッド |
ナトリウムチャネル遮断薬として有用な置換ベンズアミド
|
|
WO2017097865A1
(en)
*
|
2015-12-07 |
2017-06-15 |
Istituto Europeo Di Oncologia |
Combination of caloric restriction (cr) or igf1/insulin receptor inhibitor with lsd1 inhibitor
|
|
US9809541B2
(en)
|
2015-12-29 |
2017-11-07 |
Mirati Therapeutics, Inc. |
LSD1 inhibitors
|
|
CN109072195A
(zh)
|
2015-12-30 |
2018-12-21 |
诺华股份有限公司 |
具有增强功效的免疫效应细胞疗法
|
|
CN120661674A
(zh)
|
2016-03-15 |
2025-09-19 |
奥莱松基因组股份有限公司 |
用于治疗实体瘤的lsd1抑制剂的组合
|
|
MX2018011100A
(es)
|
2016-03-15 |
2019-01-10 |
Oryzon Genomics Sa |
Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
|
|
CN107200706A
(zh)
|
2016-03-16 |
2017-09-26 |
中国科学院上海药物研究所 |
一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途
|
|
US11034991B2
(en)
|
2016-03-16 |
2021-06-15 |
Oryzon Genomics S.A. |
Methods to determine KDM1A target engagement and chemoprobes useful therefor
|
|
WO2017172802A1
(en)
|
2016-03-30 |
2017-10-05 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
|
CN109414410B
(zh)
|
2016-04-22 |
2022-08-12 |
因赛特公司 |
Lsd1抑制剂的制剂
|
|
CN107459476B
(zh)
*
|
2016-06-03 |
2022-06-24 |
中国科学院上海药物研究所 |
反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途
|
|
WO2018020366A1
(en)
|
2016-07-26 |
2018-02-01 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Crystalline (r)-mandelate salt of (1r,2s)-2-phenylcyclopropylamine
|
|
SG10201610038SA
(en)
*
|
2016-07-29 |
2017-12-28 |
Apple Inc |
Systems and methods for management of asymmetrical multi-tapped battery packs
|
|
WO2018035259A1
(en)
|
2016-08-16 |
2018-02-22 |
Imago Biosciences, Inc. |
Methods and processes for the preparation of kdm1a inhibitors
|
|
SG11201903348UA
(en)
|
2016-10-17 |
2019-05-30 |
Genentech Inc |
Therapeutic compounds and methods of use thereof
|
|
WO2018083189A1
(en)
|
2016-11-03 |
2018-05-11 |
Oryzon Genomics, S.A. |
Biomarkers for determining responsiveness to lsd1 inhibitors
|
|
US20190256929A1
(en)
|
2016-11-03 |
2019-08-22 |
Oryzon Genomics, S.A. |
Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
|
|
US20200069677A1
(en)
|
2016-12-09 |
2020-03-05 |
Constellation Pharmaceuticals, Inc. |
Markers for personalized cancer treatment with lsd1 inhibitors
|
|
WO2018137644A1
(zh)
*
|
2017-01-24 |
2018-08-02 |
南京明德新药研发股份有限公司 |
Lsd1抑制剂及其制备方法和应用
|
|
CN110546148A
(zh)
|
2017-03-24 |
2019-12-06 |
基因泰克公司 |
作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
|
|
WO2018197583A1
(en)
|
2017-04-26 |
2018-11-01 |
Istituto Europeo Di Oncologia |
Use of a combinational therapy of lsd1 inhibitors with p21 activators in the treatment of cancer
|
|
RU2765152C2
(ru)
|
2017-05-26 |
2022-01-26 |
Тайхо Фармасьютикал Ко., Лтд. |
Новое соединение бифенила или его соль
|
|
TWI770925B
(zh)
|
2017-05-26 |
2022-07-11 |
日商大鵬藥品工業股份有限公司 |
使用有新穎聯苯化合物之抗腫瘤效果增強劑
|
|
JP6915056B2
(ja)
|
2017-05-31 |
2021-08-04 |
大鵬薬品工業株式会社 |
Ｉｎｓｍ１の発現に基づくｌｓｄ１阻害剤の治療効果の予測方法
|
|
KR20180134675A
(ko)
*
|
2017-06-09 |
2018-12-19 |
한미약품 주식회사 |
시클로프로필아민 유도체 화합물 및 이의 용도
|
|
JP2020152641A
(ja)
*
|
2017-07-07 |
2020-09-24 |
国立研究開発法人理化学研究所 |
リジン特異的脱メチル化酵素１阻害活性を有する新規化合物、その製造方法及びその用途
|
|
CA3071804A1
(en)
|
2017-08-03 |
2019-02-07 |
Oryzon Genomics, S.A. |
Use of a kdm1a inhibitor in the treatment of behavior alterations
|
|
AR112900A1
(es)
|
2017-09-13 |
2019-12-26 |
Hanmi Pharm Ind Co Ltd |
Compuesto derivado de pirazol y uso de este
|
|
WO2019068326A1
(en)
|
2017-10-05 |
2019-04-11 |
Université D'aix-Marseille |
INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
|
|
KR20190040763A
(ko)
|
2017-10-11 |
2019-04-19 |
한미약품 주식회사 |
피라졸로피리딘 유도체 화합물 및 이의 용도
|
|
KR20190040783A
(ko)
|
2017-10-11 |
2019-04-19 |
한미약품 주식회사 |
라이신 특이적 데메틸라제-1 억제제로서의 피라졸 유도체
|
|
US11685782B2
(en)
|
2017-10-23 |
2023-06-27 |
Children's Medical Center Corporation |
Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
|
|
WO2019109095A1
(en)
*
|
2017-12-01 |
2019-06-06 |
Beth Israel Deaconess Medical Center, Inc. |
Arsenic trioxide and retinoic acid compounds for treatment of idh2-associated disorders
|
|
CN108107199B
(zh)
*
|
2017-12-21 |
2019-02-12 |
广州市进德生物科技有限公司 |
一种酶化学发光法测定尿酸的检测试剂盒
|
|
EP3759098A1
(en)
|
2018-02-26 |
2021-01-06 |
Genentech, Inc. |
Pyridine-sulfonamide compounds and their use against pain and related conditions
|
|
CN111936494A
(zh)
|
2018-03-30 |
2020-11-13 |
豪夫迈·罗氏有限公司 |
作为钠通道抑制剂的取代的氢-吡啶并-吖嗪
|
|
IL279260B2
(en)
|
2018-05-11 |
2024-10-01 |
Imago Biosciences Inc |
Kdm1a inhibitors for the treatment of disease
|
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
|
AU2019303777B2
(en)
*
|
2018-07-20 |
2023-01-19 |
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. |
Salt of LSD1 inhibitor and a polymorph thereof
|
|
WO2020047198A1
(en)
|
2018-08-31 |
2020-03-05 |
Incyte Corporation |
Salts of an lsd1 inhibitor and processes for preparing the same
|
|
WO2020052647A1
(zh)
*
|
2018-09-13 |
2020-03-19 |
南京明德新药研发有限公司 |
作为lsd1抑制剂的杂螺环类化合物及其应用
|
|
WO2020052649A1
(zh)
*
|
2018-09-13 |
2020-03-19 |
南京明德新药研发有限公司 |
作为lsd1抑制剂的环丙胺类化合物及其应用
|
|
WO2020117972A1
(en)
*
|
2018-12-04 |
2020-06-11 |
The Board Of Regents Of The University Of Texas System |
Therapeutics targeting mutant adenomatous polyposis coli (apc) for the treatment of cancer
|
|
WO2020138398A1
(ja)
*
|
2018-12-28 |
2020-07-02 |
国立研究開発法人理化学研究所 |
リジン特異的脱メチル化酵素１を阻害する新規化合物、その製造方法及びその用途
|
|
CN113365996B
(zh)
*
|
2019-02-01 |
2024-09-03 |
韩美药品株式会社 |
咪唑吡啶衍生化合物以及药物组成物
|
|
JP7532386B2
(ja)
|
2019-02-01 |
2024-08-13 |
ハンミ ファーマシューティカルズ カンパニー リミテッド |
イミダゾピリジン誘導体化合物及びその用途
|
|
HRP20260110T1
(hr)
|
2019-03-20 |
2026-03-13 |
Oryzon Genomics, S.A. |
Vafidemstat za liječenje neagresivnih simptoma graničnog poremećaja osobnosti
|
|
CN113631164A
(zh)
|
2019-03-20 |
2021-11-09 |
奥莱松基因组股份有限公司 |
使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
|
|
JP2022546908A
(ja)
|
2019-07-05 |
2022-11-10 |
オリゾン・ゲノミクス・ソシエダッド・アノニマ |
Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法
|
|
CN114502561B
(zh)
*
|
2019-09-29 |
2023-12-26 |
南昌弘益药业有限公司 |
Lsd1抑制剂
|
|
US11957207B2
(en)
*
|
2020-05-28 |
2024-04-16 |
Nike, Inc. |
Foot support systems including fluid movement controllers and adjustable foot support pressure
|
|
EP3964204A1
(en)
|
2020-09-08 |
2022-03-09 |
Université d'Aix-Marseille |
Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues
|
|
CN115485282B
(zh)
*
|
2021-02-09 |
2025-09-09 |
南昌弘益药业有限公司 |
一种氧氮杂螺环化合物、其盐型及其晶型
|
|
MX2023011779A
(es)
|
2021-04-08 |
2023-11-22 |
Oryzon Genomics Sa |
Combinaciones de inhibidores de lsd1 para el tratamiento de canceres mieloides.
|
|
WO2022267495A1
(zh)
*
|
2021-06-22 |
2022-12-29 |
南昌弘益药业有限公司 |
含氮氧杂螺环类化合物及其应用
|
|
CN113512031B
(zh)
*
|
2021-07-01 |
2024-01-30 |
都创(上海)医药开发有限公司 |
一种lsd1酶抑制剂tak-418中间体化合物制备方法
|
|
WO2023067058A1
(en)
|
2021-10-20 |
2023-04-27 |
Queen Mary University Of London |
Sequential treatments and biomarkers to reverse resistance to kinase inhibitors
|
|
GB202115017D0
(en)
|
2021-10-20 |
2021-12-01 |
Univ London Queen Mary |
Sequential treatments and biomarkers to reverse resistance to kinase inhibitors
|
|
US20250275969A1
(en)
|
2022-05-09 |
2025-09-04 |
Oryzon Genomics, S.A. |
Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
|
|
CN119497613A
(zh)
|
2022-05-09 |
2025-02-21 |
奥莱松基因组股份有限公司 |
使用lsd1抑制剂治疗nf1-突变肿瘤的方法
|
|
CN120529900A
(zh)
|
2022-11-24 |
2025-08-22 |
奥莱松基因组股份有限公司 |
用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
|
|
WO2024229406A1
(en)
|
2023-05-04 |
2024-11-07 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
CN117164465B
(zh)
*
|
2023-09-04 |
2025-07-01 |
郑州大学 |
一种苯基环丙胺类化合物及其制备方法和应用
|
|
TW202530228A
(zh)
|
2023-10-12 |
2025-08-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|